查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年内分泌治疗的市场预测：按治疗领域、配销通路、给药途径、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383312

到 2030 年内分泌治疗的市场预测：按治疗领域、配销通路、给药途径、最终用户和地区进行的全球分析

Endocrinology Drugs Market Forecasts to 2030 - Global Analysis By Therapy Area, Distribution Channel, Route of Administration, End User and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球内分泌治疗市场规模为 62.5 亿美元，预计预测期内年复合成长率为 14.3%，到 2030 年将达到 159.3 亿美元。

内分泌药物是一种旨在靶向和调节内分泌系统功能的药物物质。这些药物用于治疗多种内分泌疾病和病症，包括糖尿病、甲状腺疾病、肾上腺疾病和荷尔蒙失衡。这些药物的给药方式多种多样，包括口服药物、注射和局部治疗，取决于特定病情和所涉及的荷尔蒙。

根据国际糖尿病基金会 (IDF) 2021 年的最新数据，到 2021 年，大约有 5.37 亿成年人（20-79 岁）将患有糖尿病。

内分泌疾病盛行率增加

内分泌疾病盛行率的增加是内分泌治疗市场的关键驱动因素。久坐的生活方式和不良饮食习惯等生活方式的改变导致糖尿病和肥胖等疾病的增加，并且通常需要内分泌药物来控制这两种疾病。人们越来越担心荷尔蒙失衡和相关疾病的增加是由于接触内分泌干扰物等环境因素造成的。此外，这些综合因素正在创造对内分泌治疗的持续需求，导致製药公司不断发展和行销创新治疗方法，以满足不断增长的患者群体的需求。

研究开发费用

研究和开发（R＆D）成本是内分泌治疗市场的主要抑制因素。开发新的内分泌治疗方法需要大量的财务投资，通常需要多年的临床试验。高研发成本可能会给製药公司带来财务压力，特别是如果一种有前景的药物在后期临床试验中失败的话。这些成本导致药品价格上涨，并引起医疗保健支付者和政府的审查。严格的安全性和有效性测试的需要进一步增加了财务负担。平衡创新需求与高昂的研发成本是一个困难因素，迫使製药公司在竞争激烈的内分泌市场中仔细选择和优先考虑潜在的候选药物，这一点至关重要。

联合治疗的发展

联合治疗已成为内分泌领域的一个充满希望的机会，为治疗各种内分泌疾病提供了潜在的益处。透过结合不同的药物和治疗方法，联合治疗可以产生协同效应，提高治疗效果和患者缓解率。它还可以解决抗药性等问题，并降低与给药大剂量单一药物相关的副作用风险。此外，联合治疗可以同时针对特定的疾病机製或途径，从而产生更全面和个体化的治疗策略。这种方法在糖尿病、甲状腺疾病和荷尔蒙失衡等疾病的治疗中尤其重要。随着对内分泌疾病认识的深入和新型治疗药物的开发，联合治疗的探索和发展已成为最佳化内分泌治疗效果的重要机会。因此，预计市场扩张将出现良好的成长。

法规挑战

法规挑战对内分泌市场构成重大威胁。内分泌疗法的开发、核准和商业化受到严格且不断发展的法规的约束。 FDA 等法规机构制定了严格的标准来确保安全性和有效性，这可能会导致核准时间更长和合规成本更高。遵守这些标准需要大量的财力和人力资源，这可能会抑制研发投资。此外，法规要求的变化可能会影响市场形势，我们必须不断适应。因此，这些挑战阻碍了市场的成长。

COVID-19 的影响

COVID-19 的爆发对内分泌治疗市场产生了重大影响。医疗保健系统对病毒管理的关注导致了内分泌疾病诊断和治疗的混乱。此外，供应链中断和药物短缺给维持内分泌治疗的稳定供应带来了挑战。然而，大流行加速了远端医疗的普及，为远端监控和处方管理提供了新途径。毕竟，内分泌治疗市场在大流行期间面临复杂的情况，包括延误、药物短缺和不断变化的医疗服务模式。

预计糖尿病药物领域在预测期内将是最大的

由于糖尿病患者数量的增加、糖尿病治疗药物开发的增加以及糖尿病治疗研发投入的增加，预计糖尿病治疗领域将占据最大份额。全球糖尿病的高盛行率以及缺乏有前途且有效的糖尿病治疗药物也推动了这一领域的成长。此外，主要企业和政府机构增加对糖尿病药物开发的投资预计将推动该领域的成长。因此，由于糖尿病患者数量的增加以及用于开发抗糖尿病药物的研究资金的增加，预计糖尿病细分市场将显着增长。

医院药房业务预计在预测期内年复合成长率最高

预计医院药局部门在预测期内将出现良好成长。内分泌药物旨在解决荷尔蒙失衡和相关疾病。在这一领域，医院药局是重要的配送中心，确保患者以受控且及时的方式获得正确的药物。他们还在患者教育中发挥重要作用，帮助患者了解内分泌药物的正确使用和潜在副作用。此外，医院药房与内分泌科医生合作，确保治疗计划（通常涉及复杂的药物治疗）得到有效实施。因此，医院药局是内分泌治疗市场的重要组成部分，有助于优化病患照护和内分泌疾病管理。

比最大的地区

由于人口高龄化加剧增加了内分泌疾病的风险，北美在预测期内获得了最大的市场占有率。美国和加拿大肥胖病例的增加导致许多内分泌疾病的发生率增加，包括糖尿病、胰岛素抗性和甲状腺问题。糖尿病是最常见的内分泌疾病，盛行率很高，对区域市场的收益贡献很大。此外，美国糖尿病教育者美国和美国糖尿病协会等组织正在推动扩大该地区的病患教育。

复合年复合成长率最高的地区：

由于生长激素缺乏症盛行率上升以及该地区研发的预期成长，预计亚太地区在预测期内将实现盈利成长。该地区的内分泌治疗市场可能会受益于与内分泌系统和糖尿病相关的癌症（包括末期肾病）盛行率的不断上升。此外，社会对更年期性交困难和外阴阴道萎缩等罕见内分泌疾病的认识不断提高，预计将在估计期间推动市场成长。此外，各种研究范式的实施，例如引入治疗内分泌疾病的新药和药物组合，预计也将促进该地区的成长。

提供免费客製化：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球内分泌治疗市场：依治疗领域

  • 糖尿病药物
  • 生长激素紊乱
  • 治疗甲状腺激素失调的药物
  • 睾酮替代疗法
  • 骨质疏鬆症
  • 肾上腺皮质功能不全
  • 性腺功能减退症
  • 其他治疗领域

第6章全球内分泌治疗市场：依配销通路

  • 医院药房
  • 网路药房
  • 零售药房
  • 其他配销通路

第7章全球内分泌治疗市场：依给药途径

  • 口服
  • 经皮的
  • 注射

第8章全球内分泌治疗市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 其他最终用户

第9章全球内分泌治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Abbott Laboratories,
  • Eli Lilly And Company
  • F. Hoffmann La Roche Ltd.
  • Novartis International AG
  • Pfizer Inc.
  • Alacer Corporation
  • Novo Nordisk A/S
  • Facet Biotech Corporation
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Merck KGaA
  • AstraZeneca Plc
  • Lee Pharmaceuticals
  • MannKind
  • Acerus Pharmaceuticals Corp
  • Bayer AG
  • Endo International Plc
  • Beta Cell NV
  • Hanmi Pharm Co. Ltd
  • Ipsen Pharma
Product Code: SMRC24162

According to Stratistics MRC, the Global Endocrinology Drugs Market is accounted for $6.25 billion in 2023 and is expected to reach $15.93 billion by 2030 growing at a CAGR of 14.3% during the forecast period. Endocrinology drugs are pharmaceutical substances designed to target and regulate the functions of the endocrine system. These drugs are used to treat a wide range of endocrine disorders and conditions, such as diabetes, thyroid disorders, adrenal gland disorders, and hormonal imbalances. These drugs can be administered in various forms, including oral medications, injections, and topical treatments, depending on the specific condition and the hormone involved.

According to the International Diabetic Foundation (IDF) 2021 update, approximately 537 million adults (20-79 years) were living with diabetes in 2021.

Market Dynamics:

Driver:

Growing prevalence of endocrine disorders

The growing prevalence of endocrine disorders is a significant driver of the endocrinology drug market. Lifestyle changes, including sedentary behaviour and poor dietary habits, have led to an increase in conditions like diabetes and obesity, both of which often require endocrinology medications for management. The increasing prevalence of hormonal imbalances and associated diseases has raised concerns and been attributed to environmental factors, such as exposure to endocrine-disrupting substances. Furthermore, these combined factors create a sustained demand for endocrinology drugs, providing growth for pharmaceutical companies to develop and market innovative treatments that address the needs of an expanding patient population.

Restraint:

Research and development costs

Research and Development (R&D) costs are a significant restraint in the endocrinology drugs market. Developing new endocrinology medications demands substantial financial investments, often spanning many years and clinical trials. High R&D expenditures can lead to financial strain for pharmaceutical companies, especially if promising drugs fail in late-stage trials. These costs contribute to elevated drug prices, attracting scrutiny from healthcare payers and governments. The need for rigorous safety and efficacy testing further increases the financial burden. Balancing the imperative for innovation with the substantial R&D expenses is a challenging restraint, making it essential for pharmaceutical firms to carefully select and prioritize potential drug candidates in the highly competitive endocrinology market.

Opportunity:

Development of combination therapies

Combination therapies have emerged as a promising opportunity in the field of endocrinology, offering potential benefits for the treatment of various endocrine disorders. By combining different drugs or treatment approaches, combination therapies can provide synergistic effects, improving treatment outcomes and patient response rates. They can also help address issues such as drug resistance and reduce the risk of adverse effects associated with high doses of a single medication. Moreover, combination therapies offer the potential to target specific disease mechanisms or pathways simultaneously, leading to more comprehensive and personalised treatment strategies. This approach is especially relevant in the management of conditions like diabetes, thyroid disorders, and hormonal imbalances. With ongoing advancements in understanding endocrine disorders and the development of novel therapeutic agents, the exploration and development of combination therapies present a significant opportunity to optimise treatment outcomes in endocrinology. Thus, there is lucrative growth for market expansion.

Threat:

Regulatory challenges

Regulatory challenges present a substantial threat to the endocrinology market. The development, approval, and commercialization of endocrinology drugs are subject to stringent and evolving regulations. Regulatory agencies, such as the FDA, impose rigorous standards to ensure safety and efficacy, which can lead to protracted approval timelines and high compliance costs. Compliance with these standards demands substantial financial and human resources, potentially discouraging investment in research and development. Additionally, changes in regulatory requirements can impact the market landscape, necessitating constant adaptation. Thus, these challenges are hampering market growth.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the endocrinology drugs market. The healthcare system's focus on managing the virus led to disruptions in the diagnosis and treatment of endocrine disorders. Additionally, supply chain disruptions and drug shortages posed challenges in maintaining a steady supply of endocrinology drugs. However, the pandemic also accelerated telehealth adoption, offering new avenues for remote monitoring and prescription management. Ultimately, the endocrinology drugs market faced a complex landscape of delays, drug shortages, and evolving healthcare delivery models during the pandemic.

The Diabetes Drugs segment is expected to be the largest during the forecast period

The Diabetes Drugs segment is estimated to hold the largest share, owing to the increase in cases of diabetes, the rise in the development of diabetic drugs, and the increase in investment in the development of diabetic drug research. Also, the high prevalence of diabetes across the globe and the unavailability of promising and effective drug products for the treatment of diabetes spurs the growth of this segment. Furthermore, a rise in investments in the development of diabetic drugs by key players or government agencies is expected to fuel the growth of the segment. Hence, due to the rise in cases of diabetes and the increase in research funding for the development of diabetic drugs, the diabetes segment is expected to witness significant growth.

The Hospital Pharmacies segment is expected to have the highest CAGR during the forecast period

The Hospital Pharmacies segment is anticipated to have lucrative growth during the forecast period. Endocrinology drugs are designed to address hormonal imbalances and related conditions. In this segment, hospital pharmacies serve as key distribution points; ensuring patients receive the right medications in a controlled and timely manner. They also play a pivotal role in patient education, helping individuals understand the proper use and potential side effects of endocrinology drugs. Moreover, hospital pharmacies collaborate with endocrinologists to ensure tailored treatment plans, often involving complex medication regimens, are effectively implemented. Hence, hospital pharmacies are vital components of the endocrinology drugs market, facilitating optimal patient care and management of endocrine disorders.

Region with largest share:

North America commanded the largest market share during the extrapolated period due to the growing ageing population, which increases the risk of endocrine disorders. Increases in the incidence of a number of endocrine disorders, including diabetes, insulin resistance, and thyroid issues, can be attributed to the rise in obesity cases in the US and Canada. The most prevalent endocrine condition, diabetes, has a high prevalence and contributes significantly to regional market income. Moreover, the American Association of Diabetes Educators and the American Diabetes Association, among other groups, are driving the expansion of the patient education sector in the region.

Region with highest CAGR:

Asia- Pacific region is expected to witness profitable growth over the projection period, owing to a rise in the prevalence of growth hormone deficiency and the expected growth of research and development in the region. The market for endocrinology drugs in the area will benefit from an increase in the incidence of cancers related to the endocrine system and diabetes, including end-stage renal disease. Furthermore, throughout the duration of the estimated time frame, rising public awareness of infrequently occurring endocrine disorders-such as dyspareunia and vulvar and vaginal atrophy caused by menopause-is anticipated to fuel the market's growth. Various research paradigms carried out, such as the introduction of novel drugs and combination pharmaceuticals for the treatment of endocrine disorders, are also expected to boost the region's growth.

Key players in the market

Some of the key players in the Endocrinology Drugs Market include: Abbott Laboratories, Eli Lilly And Company, F. Hoffmann La Roche Ltd., Novartis International AG, Pfizer Inc., Alacer Corporation , Novo Nordisk A/S, Facet Biotech Corporation, Sanofi, Takeda Pharmaceutical Company Limited, Merck KGaA, AstraZeneca Plc, Lee Pharmaceuticals, MannKind, Acerus Pharmaceuticals Corp, Bayer AG, Endo International Plc, Beta Cell NV, Hanmi Pharm Co. Ltd and Ipsen Pharma.

Key Developments:

In March 2023, Eton Pharmaceuticals, a pharmaceutical company focused on developing and commercializing treatments for rare diseases, acquired a rare disease product candidate, ET-600, from Tulex Pharmaceuticals. ET-600 is an innovative product candidate under development for treating an endocrinology condition estimated to impact less than 5,000 pediatric patients in the United States.

In February 2023, Akums Drugs and Pharmaceutical Limited, a contract drug manufacturing company, received approval from the Drug Controller-General of India (DCGI) for their product Lobeglitazone, an anti-diabetic drug. The drug is a new formulation manufactured specifically for type 2 diabetic patients by helping them improve pancreatic beta-cell function.

Therapy Areas Covered:

  • Diabetes Drugs
  • Growth Hormone Disorders
  • Thyroid Hormone Disorder Drugs
  • Testosterone Replacement Therapy
  • Osteoporosis
  • Adrenal insufficiency
  • Hypogonadism
  • Other Therapy Areas

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

Route of Administrations Covered:

  • Oral
  • Transdermal
  • Injectable

End Users Covered:

  • Ambulatory Surgical Centers
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Endocrinology Drugs Market, By Therapy Area

  • 5.1 Introduction
  • 5.2 Diabetes Drugs
  • 5.3 Growth Hormone Disorders
  • 5.4 Thyroid Hormone Disorder Drugs
  • 5.5 Testosterone Replacement Therapy
  • 5.6 Osteoporosis
  • 5.7 Adrenal insufficiency
  • 5.8 Hypogonadism
  • 5.9 Other Therapy Areas

6 Global Endocrinology Drugs Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Hospital Pharmacies
  • 6.3 Online Pharmacies
  • 6.4 Retail Pharmacies
  • 6.5 Other Distribution Channels

7 Global Endocrinology Drugs Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Transdermal
  • 7.4 Injectable

8 Global Endocrinology Drugs Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgical Centers
  • 8.3 Hospitals
  • 8.4 Other End Users

9 Global Endocrinology Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories,
  • 11.2 Eli Lilly And Company
  • 11.3 F. Hoffmann La Roche Ltd.
  • 11.4 Novartis International AG
  • 11.5 Pfizer Inc.
  • 11.6 Alacer Corporation
  • 11.7 Novo Nordisk A/S
  • 11.8 Facet Biotech Corporation
  • 11.9 Sanofi
  • 11.10 Takeda Pharmaceutical Company Limited
  • 11.11 Merck KGaA
  • 11.12 AstraZeneca Plc
  • 11.13 Lee Pharmaceuticals
  • 11.14 MannKind
  • 11.15 Acerus Pharmaceuticals Corp
  • 11.16 Bayer AG
  • 11.17 Endo International Plc
  • 11.18 Beta Cell NV
  • 11.19 Hanmi Pharm Co. Ltd
  • 11.20 Ipsen Pharma

List of Tables

  • Table 1 Global Endocrinology Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Endocrinology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 3 Global Endocrinology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 4 Global Endocrinology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 5 Global Endocrinology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 6 Global Endocrinology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 7 Global Endocrinology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 8 Global Endocrinology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 9 Global Endocrinology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 10 Global Endocrinology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 11 Global Endocrinology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 12 Global Endocrinology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 13 Global Endocrinology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 14 Global Endocrinology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 15 Global Endocrinology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 16 Global Endocrinology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 17 Global Endocrinology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 18 Global Endocrinology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 19 Global Endocrinology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 20 Global Endocrinology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Endocrinology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 22 Global Endocrinology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Endocrinology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 26 North America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 27 North America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 28 North America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 29 North America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 30 North America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 31 North America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 32 North America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 33 North America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 34 North America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 35 North America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 36 North America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 37 North America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 38 North America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 39 North America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 40 North America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 41 North America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 42 North America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 43 North America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 44 North America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 45 North America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 49 Europe Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 50 Europe Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 51 Europe Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 52 Europe Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 53 Europe Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 54 Europe Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 55 Europe Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 56 Europe Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 57 Europe Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 58 Europe Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 59 Europe Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 60 Europe Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 61 Europe Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 62 Europe Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 63 Europe Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 64 Europe Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 65 Europe Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 66 Europe Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 67 Europe Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 68 Europe Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 69 Europe Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 72 Asia Pacific Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 73 Asia Pacific Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 74 Asia Pacific Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 75 Asia Pacific Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 76 Asia Pacific Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 77 Asia Pacific Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 78 Asia Pacific Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 79 Asia Pacific Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 80 Asia Pacific Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 81 Asia Pacific Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 82 Asia Pacific Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 83 Asia Pacific Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 84 Asia Pacific Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 85 Asia Pacific Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 86 Asia Pacific Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 87 Asia Pacific Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 88 Asia Pacific Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 89 Asia Pacific Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 90 Asia Pacific Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 91 Asia Pacific Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 92 Asia Pacific Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 95 South America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 96 South America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 97 South America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 98 South America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 99 South America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 100 South America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 101 South America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 102 South America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 103 South America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 104 South America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 105 South America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 106 South America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 107 South America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 108 South America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 109 South America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 110 South America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 111 South America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 112 South America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 113 South America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 114 South America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 115 South America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
  • Table 118 Middle East & Africa Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
  • Table 119 Middle East & Africa Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
  • Table 120 Middle East & Africa Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
  • Table 121 Middle East & Africa Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
  • Table 122 Middle East & Africa Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
  • Table 123 Middle East & Africa Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
  • Table 124 Middle East & Africa Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
  • Table 125 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
  • Table 126 Middle East & Africa Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 127 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 128 Middle East & Africa Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 129 Middle East & Africa Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 130 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 131 Middle East & Africa Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 132 Middle East & Africa Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 133 Middle East & Africa Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 134 Middle East & Africa Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 135 Middle East & Africa Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 136 Middle East & Africa Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 137 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 138 Middle East & Africa Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)